MONTREAL, June 25 /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX:PLI)
("ProMetic") announced today that it has further confirmed the efficacy of the
prion capture resins developed by Pathogen Removal and Diagnostic Technologies
Inc. ("PRDT")' in the removal of prions from different solutions, including
mixtures of proteins containing high concentrations of specific proteins such
as 25% albumin and 3% immunoglobulin solutions without affecting the
concentration of the proteins. Plasma-derived albumin and immunoglobulin
proteins are commonly used as therapeutics. Furthermore, proteins such as
albumin are also regularly used as non-active stabilizing ingredients in the
formulation of biopharmaceutical products.
"This has far reaching implications for the biopharmaceutical industry.
It offers the opportunity to provide an additional safety element by including
prion-depleted human blood-derived or animal-derived products in the
formulation and manufacture of some of these high-value therapeutics," stated
Mr. Pierre Laurin, ProMetic's President and Chief Executive Officer.
In addition, the evaluation of PRDT resins established their ability to
efficiently remove infectious prion protein from whole human plasma, a complex
mixture of hundreds of different proteins, and demonstrated that the ligands
developed by PRDT targets the prion protein, and can bind that compound even
under the competition of several proteins, without significantly binding any
of the proteins vital for plasma.
This corroboration of the PRDT resins' performance follows on the
June 10th announcement of Octopharma AG's recent implementation of PRDT's
prion removal resin into their manufacturing process of Octaplas(R). For
additional information on this announcement, please visit ProMetic's Newsroom
Dr. Patrick Gurgel, ProMetic's Senior Research Scientist addressed the
information on the PRDT resins in a poster titled "Removal of prion
infectivity from plasma-derived products" during the Recovery of Biological
Products 13 Conference held in Quebec City, Quebec from June 22 - 27, 2008.
The poster is available on ProMetic's website at
About Pathogen Removal and Diagnostic Technologies Inc.
Pathogen Removal and Diagnostic Technologies Inc. ("PRDT") is a joint
venture established in April 2002 by The American Red Cross and ProMetic Life
Sciences Inc., and allows for the exchange of technology and knowledge between
the two organizations. PRDT's main goal is to develop products and devices to
remove and detect different pathogens from biological sources. This research
augments work that ProMetic, the American Red Cross and PRDT's scientific
founders have been conducting independently for many years.
About ProMetic Life Sciences Inc.
ProMetic Life Sciences Inc. (www.prometic.com) is a biopharmaceutical
company specialized in the research, development, manufacture and marketing of
a variety of commercial applications derived from its proprietary Mimetic
Ligand(TM) technology. This technology is used in large-scale purification of
biologics and the elimination of pathogens. ProMetic is also active in
therapeutic drug development with the mission to bring to market effective,
innovative, lower cost, less toxic products for the treatment of hematology
and cancer. Its drug discovery platform is focused on replacing complex,
expensive proteins with synthetic "drug-like" protein mimetics. Headquartered
in Montréal (Canada), ProMetic has R&D facilities in the U.K., the U.S. and
Canada, manufacturing facilities in the U.K. and business development
activities in the U.S., Europe, Asia and in the Middle-East.
Forward Looking Statements
This press release contains forward-looking statements about ProMetic's
objectives, strategies and businesses that involve risks and uncertainties.
These statements are "forward-looking" because they are based on our current
expectations about the markets we operate in and on various estimates and
assumptions. Actual events or results may differ materially from those
anticipated in these forward-looking statements if known or unknown risks
affect our business, or if our estimates or assumptions turn out to be
inaccurate. Such risks and assumptions include, but are not limited to,
ProMetic's ability to develop, manufacture, and successfully commercialize
value-added pharmaceutical products, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of ProMetic to take advantage of business opportunities
in the pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. You will find a more
detailed assessment of the risks that could cause actual events or results to
materially differ from our current expectations on page 21 of ProMetic's
Annual Information Form for the year ended December 31, 2007, under the
heading "Risk Factors". As a result, we cannot guarantee that any
forward-looking statement will materialize. We assume no obligation to update
any forward-looking statement even if new information becomes available, as a
result of future events or for any other reason, unless required by applicable
securities laws and regulations.
For further information:
For further information: Company Inquiries: Pierre Laurin, President and
CEO, ProMetic Life Sciences Inc., (514) 341-2115, firstname.lastname@example.org; Anne
Leduc, Manager, Investor Relations & Communications, ProMetic Life Sciences
Inc., (514) 341-2115, email@example.com; Dominic Sicotte, Echoes Financial
Network Inc., (514) 842-9551, firstname.lastname@example.org; Investor
Relations: Bruce Voss, Lippert/Heilshorn & Associates, (310) 691-7100,
BVoss@lhai.com; Kim Golodetz, Lippert/Heilshorn & Associates, (212) 838-3777,
KGolodetz@lhai.com; Media Relations: Jules Abraham, Lippert/Heilshorn &
Associates, (212) 838-3777, JAbraham@lhai.com